Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
1
SONN Quote, Financials, Valuation and Earnings
Last price:
$1.26
Seasonality move
:
-4.34%
Day range:
$1.26 - $1.26
52-week range:
$1.08 - $19.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
15.39x
Volume:
--
Avg. volume:
1M
1-year change:
-26.32%
Market cap:
$7.9M
Revenue:
$18.6K
EPS (TTM):
-$3.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-- | -$0.49 | -100% | -91.25% | $20.00 |
|
DNLI
Denali Therapeutics, Inc.
|
$1M | -$0.76 | 559.6% | -13.28% | $32.29 |
|
EXAS
EXACT Sciences Corp.
|
$810.6M | $0.16 | 20.65% | -84.17% | $103.67 |
|
HYPD
Hyperion DeFi, Inc.
|
-- | -- | -- | -- | -- |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $222.78 |
|
JANX
Janux Therapeutics, Inc.
|
$3.1M | -$0.61 | 599.64% | -80.26% | $66.24 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
$1.26 | $20.00 | $7.9M | -- | $0.00 | 0% | 3.33x |
|
DNLI
Denali Therapeutics, Inc.
|
$19.96 | $32.29 | $2.9B | -- | $0.00 | 0% | 6.62x |
|
EXAS
EXACT Sciences Corp.
|
$101.06 | $103.67 | $19.1B | -- | $0.00 | 0% | 6.15x |
|
HYPD
Hyperion DeFi, Inc.
|
$3.89 | -- | $31.5M | -- | $0.00 | 0% | 100.83x |
|
INSM
Insmed, Inc.
|
$204.00 | $222.78 | $43.5B | -- | $0.00 | 0% | 86.81x |
|
JANX
Janux Therapeutics, Inc.
|
$16.51 | $66.24 | $993M | -- | $0.00 | 0% | 100.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-2.31% | 4.130 | 1.75% | 0.06x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
EXAS
EXACT Sciences Corp.
|
50.33% | 1.709 | 24.46% | 2.24x |
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 19.509 | 13.53% | 2.04x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
JANX
Janux Therapeutics, Inc.
|
2.27% | -0.738 | 1.54% | 35.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-$22.2K | -$3.8M | -1563.18% | -1790.87% | -284.94% | -$1.8M |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
EXAS
EXACT Sciences Corp.
|
$583.9M | $16.3M | -18.87% | -38% | 1.91% | $190M |
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
JANX
Janux Therapeutics, Inc.
|
$9.5M | -$35.3M | -10.68% | -10.94% | -352.51% | -$12.9M |
Sonnet BioTherapeutics Holdings, Inc. vs. Competitors
-
Which has Higher Returns SONN or DNLI?
Denali Therapeutics, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of --. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.29 which suggests that it could grow by 61.39%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 DNLIDenali Therapeutics, Inc.17 0 0 -
Is SONN or DNLI More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.
-
Which is a Better Dividend Stock SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Denali Therapeutics, Inc. quarterly revenues of --. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 3.33x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns SONN or EXAS?
EXACT Sciences Corp. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -2.3%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87% beat EXACT Sciences Corp.'s return on equity of -38%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M EXASEXACT Sciences Corp.68.64% -$0.10 $5B -
What do Analysts Say About SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $103.67 which suggests that it could grow by 2.58%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 EXASEXACT Sciences Corp.3 18 0 -
Is SONN or EXAS More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.
-
Which is a Better Dividend Stock SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 3.33x versus 6.15x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M EXASEXACT Sciences Corp.6.15x -- $850.7M -$19.6M
-
Which has Higher Returns SONN or HYPD?
Hyperion DeFi, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of --. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87% beat Hyperion DeFi, Inc.'s return on equity of -143.24%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M HYPDHyperion DeFi, Inc.-- $0.05 $79.2M -
What do Analysts Say About SONN or HYPD?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Hyperion DeFi, Inc. has an analysts' consensus of -- which suggests that it could fall by -48.59%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 HYPDHyperion DeFi, Inc.0 0 0 -
Is SONN or HYPD More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Hyperion DeFi, Inc. has a beta of 2.805, suggesting its more volatile than the S&P 500 by 180.539%.
-
Which is a Better Dividend Stock SONN or HYPD?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hyperion DeFi, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Hyperion DeFi, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or HYPD?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Hyperion DeFi, Inc. quarterly revenues of $302.5K. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M is lower than Hyperion DeFi, Inc.'s net income of $6.6M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Hyperion DeFi, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 3.33x versus 100.83x for Hyperion DeFi, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M HYPDHyperion DeFi, Inc.100.83x -- $302.5K $6.6M
-
Which has Higher Returns SONN or INSM?
Insmed, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -259.95%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Insmed, Inc. has an analysts' consensus of $222.78 which suggests that it could grow by 9.21%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Insmed, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 INSMInsmed, Inc.17 1 0 -
Is SONN or INSM More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M is higher than Insmed, Inc.'s net income of -$370M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 3.33x versus 86.81x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M INSMInsmed, Inc.86.81x -- $142.3M -$370M
-
Which has Higher Returns SONN or JANX?
Janux Therapeutics, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -243.13%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M -
What do Analysts Say About SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $66.24 which suggests that it could grow by 301.18%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Janux Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Janux Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 JANXJanux Therapeutics, Inc.15 1 0 -
Is SONN or JANX More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 3.33x versus 100.11x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M JANXJanux Therapeutics, Inc.100.11x -- $10M -$24.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.66% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.94% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 4.41% over the past day.
